.
.
.
EXHIBIT 99.1
Contact:
- --------
Investors: Media:
Ann Tanabe Daniel Budwick
Director, Investor Relations and Corporate Communications BMC Communications
Encysive Pharmaceuticals (212) 477-9007 ext. 14
(713) 796-8822
Hershel Berry
The Trout Group
(415) 392-3385
FOR IMMEDIATE RELEASE
- ---------------------
ENCYSIVE PHARMACEUTICALS FILES $150 MILLION UNIVERSAL SHELF REGISTRATION
STATEMENT
Houston, TX- (June 7, 2004) - Encysive Pharmaceuticals (Nasdaq: ENCY) today
announced that it has filed a universal shelf registration statement on Form S-3
with the Securities and Exchange Commission ("SEC"). Once the registration
statement is reviewed and declared effective by the SEC, the Company will be
able to offer and sell up to $150.0 million of its debt securities, common
stock, preferred stock, depositary shares, warrants, purchase contracts and
units from time to time in one or more offerings. The terms of any such future
offerings would be established at the time of such offering. A registration
statement relating to these securities has been filed with the SEC but has not
yet become effective. These securities may not be sold nor may offers to buy be
accepted prior to the time the registration statement becomes effective. This
press release shall not constitute an offer to sell or the solicitation of an
offer to buy, nor shall there be any sale of these securities in any state in
which such offer, solicitation, or sale would be unlawful prior to registration
or qualification under the securities laws of any such state. Any offer of these
securities will be made solely by means of the prospectus included in the
registration statement and any prospectus supplement that may be issued in
respect of any such offering.
ABOUT ENCYSIVE PHARMACEUTICALS
Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, Thelin, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.
This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of research
and clinical goals and milestones of product candidates, attainment of required
government approvals, sales levels of our products and availability of financing
and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The Company undertakes no duty to update or revise these
forward-looking statements.
# # #